Trial reportTuberculosis (Edinburgh, Scotland)2012
Anti-phospholipid antibody levels as biomarker for monitoring tuberculosis treatment response.
Trial report in Tuberculosis (Edinburgh, Scotland), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Antiphospholipid antibodies in acute and post-treatment Lyme disease.Infection and immunity · 2026Article
- Phospholipids and phospholipase A1 as antigens during the course of experimental Trypanosoma cruzi infection.Memorias do Instituto Oswaldo Cruz · 2025Article
- Serum anti-lipid antibodies in patients affected by leprosy in a high-burden municipality in Brazil: a cross-sectional study.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
- Application of Monoclonal Anti-Mycolate Antibodies in Serological Diagnosis of Tuberculosis.Tropical medicine and infectious disease · 2024Article
- Revolutionizing control strategies against Mycobacterium tuberculosis infection through selected targeting of lipid metabolism.Cellular and molecular life sciences : CMLS · 2023Review
- Characteristics of Serum Autoantibody Repertoire and Immune Subgroup Variation of Tuberculosis-Associated Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2023Article
- Tuberculosis and Autoimmunity.Pathophysiology : the official journal of the International Society for Pathophysiology · 2022Review
- Antiphospholipid autoantibodies in Lyme disease arise after scavenging of host phospholipids by Borrelia burgdorferi.The Journal of clinical investigation · 2022Article
- Serological biomarkers for monitoring response to treatment of pulmonary and extrapulmonary tuberculosis in children and adolescents.Tuberculosis (Edinburgh, Scotland) · 2020Article
- Current Understanding of Natural Antibodies and Exploring the Possibilities of Modulation Using Veterinary Models. A Review.Frontiers in immunology · 2020Review
- Tuberculosis Infection in Chinese Patients with Giant Cell Arteritis.Scientific reports · 2019Article
- Thromboses in tuberculosis are linked to antiphosphatidylethanolamine antibodies levels: A cross-sectional study.Journal of clinical tuberculosis and other mycobacterial diseases · 2019Article
- Environmental Triggers of Autoreactive Responses: Induction of Antiphospholipid Antibody Formation.Frontiers in immunology · 2019Review
- Both B-1a and B-1b cells exposed to Mycobacterium tuberculosis lipids differentiate into IgM antibody-secreting cells.Immunology · 2018Article
- Anti-phospholipid Antibodies and Smoking: An Overview.Clinical reviews in allergy & immunology · 2017Review
- Impairment of Wnt/β-catenin signaling in blood cells of patients with severe cavitary pulmonary tuberculosis.PloS one · 2017Article
- IgG, IgM and IgA antibodies against the novel polyprotein in active tuberculosis.BMC infectious diseases · 2014Article
- The Bandim TBscore--reliability, further development, and evaluation of potential uses.Global health action · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
Abstract
Standard methods to monitor tuberculosis (TB) treatment response rely on sputum microscopy and culture conversion. Alternatives to these methods are needed for those patients whose sputum tests are smear or culture negative. Here, we examine anti-phospholipid IgM antibody level changes as a biomarker for treatment response in smear positive TB patients. Serum samples were obtained from 40 pulmonary TB patients at the start and end of the intensive phase treatment (IPT) from the CDC-TB Trials Consortium randomized clinical trial in Kampala, Uganda. Samples were screened by ELISA for IgM levels against five phospholipids found in Mycobacterium tuberculosis and host cells. Lipid antigens included cardiolipin (CL), phosphatidyl inositol (PI), phosphatidyl ethanolamine (PE), phosphatidyl choline (PTC), and sphingolipid (SL). Levels of IgM against all phospholipids significantly decreased (p = 0.034, 0.001, 0.008 0.008, 0.040, respectively) following anti-TB drug treatment in patients without lung cavitary disease at baseline. The mean sensitivity of this test in these patients was 83% when the IgM response to a single lipid antigen was used; it was >90% when responses to 2 or more lipids were assessed. In contrast, cavitary TB patients showed an overall IgM increase, with a significant rise against PE (p = 0.025). There was no significant difference in the change in antibody levels between patients who remained culture-positive and those who culture-converted after 40 doses of drug therapy. The measurement of IgM anti-phospholipid antibodies may be a useful biomarker to monitor treatment response in non-cavitary TB patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.